Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Dec 5;13:1027687. doi: 10.3389/fphar.2022.1027687

Curcumae Rhizoma - combined with Sparganii Rhizoma in the treatment of liver cancer: Chemical analysis using UPLC-LTQ-Orbitrap MSn, network analysis, and experimental assessment

Jing Wei 1,2,, Xiaoping Wang 1,2,, Ying Dong 1,2, Xiangjian Zhong 1,2, Xueyang Ren 1,2, Ruolan Song 1,2, Jiamu Ma 1,2, Axiang Yu 1,2, Qiqi Fan 1,2, Jianling Yao 1,2, Dongjie Shan 1,2, Fang Lv 1,2, Yuan Zheng 1,2, Qingyue Deng 1,2, Xianxian Li 1,2, Yingyu He 1,2, Shusheng Fan 3, Chongjun Zhao 1,2, Xiuhuan Wang 1,2,4,*,, Ruijuan Yuan 1,*,, Gaimei She 1,2,*,
PMCID: PMC9764015  PMID: 36561345

Abstract

Objective: Curcumae RhizomaSparganii Rhizoma (CR-SR) is a traditional botanical drug pair that can promote blood circulation, remove blood stasis, and treat tumors in clinics. The aim of the present study was to investigate the therapeutic material basis and potential mechanisms of CR-SR, CR, and SR for the treatment of liver cancer.

Method: The chemical profile analyses of CR-SR, CR, and SR were performed by molecular networking and UPLC-LTQ-Orbitrap MSn. The anti-liver cancer activities of CR-SR, CR, and SR were assessed by using a zebrafish xenograft model in vivo for the first time and detected by the HepG2 cell model in vitro. Combining the network analysis and molecular docking, real-time quantitative polymerase chain reaction (RT-qPCR) experiments were undertaken to further explore the mechanisms of CR-SR, CR, and SR for the treatment of liver cancer.

Results: In total, 65 components were identified in CR-SR, CR, and SR. Based on the clusters of molecular networking, a total of 12 novel diarylheptanoids were identified from CR-SR and CR. By combining our results with information from the literature, 32 sesquiterpenoids and 21 cyclic dipeptides were identified from CR-SR, CR, and SR. The anti-liver cancer activities were observed in both the drug pair and the single botanical drugs in vitro and in vivo, and the order of activity was CR-SR > CR > SR. They could downregulate the expression of proto-oncogene tyrosine-protein kinase Src (SRC), epidermal growth factor receptor (EGFR), estrogen receptor-α (ESR1), prostaglandin endoperoxide synthase 2 (PTGS2), and amyloid precursor protein (APP).

Conclusion: Taken together, the present study provided an experimental basis for the therapeutic material basis and potential molecular mechanisms of CR-SR, CR, and SR. This study provided a novel insight for objective clinical treatment of liver cancer.

Keywords: Curcumae Rhizoma - Sparganii Rhizoma , liver cancer, molecular networking, UPLC-LTQ-Orbitrap MSn , zebrafish xenograft model

1 Introduction

A drug pair in traditional Chinese medicine (TCM) refers to two botanical drugs that exhibit synergistic pharmaceutical and/or detoxification activities, playing an important role in the exploration of general botanical drug compatibility (Wang et al., 2012; Yu et al., 2019). The compatibility of CR and SR is a traditional drug pair for promoting blood circulation and removing blood stasis in clinics, which shows a tendency to reinforce each other (Xu et al., 2015). According to traditional Chinese medicine, activating blood circulation and removing blood stasis could dredge the meridians, improve microcirculation, and adjust and strengthen immune function to dampen cancer and shrink the lump (Lu and Li, 2009). Modern pharmacological studies have shown that the occurrence and development of tumors are related to angiogenesis and the abnormal blood coagulation system. The current research and clinical practice mostly focus on anti-liver cancer activities (Xu et al., 2015).

Our team has been committed to studying the anti-cancer activities of CR-SR, CR, and SR. The results showed their broad-spectrum anti-tumor activity in vitro. Also, the activity of the drug pair was better than the single drug (Liu et al., 2021). The anti-liver cancer activity in vivo of CR-SR, CR, and SR is still obscure. Zebrafish have been widely used in tumor research because they have highly conserved oncogenes, tumor suppressor genes, and cell cycle regulatory genes with humans. The features of zebrafish in rapid cell division and delayed apoptosis in embryos are similar to those of human tumors (Lu et al., 2011; Shuo et al., 2018). Therefore, zebrafish can test activity evaluation and gene expression in mechanism research.

The linear diarylheptanoids of CR-SR, CR, and SR were determined by the UPLC-MS method in previous research (Chang et al., 2020). Molecular networking is a technique used for rapid and massive identification of known compounds, similar compounds, and discovering new compounds in recent years (Le Daré et al., 2021; Zhao et al., 2021). The combination of LC-MS and molecular networking can make the analysis of MS data less time-consuming and difficult.

Network analysis is a very promising approach for finding potential drug targets (Tao et al., 2013). Constructing a multi-level network through omics data analysis and computer simulation methods provides a new idea for the systematic research of the complex system of TCM (Li and Zhang, 2013). Molecular docking is a method of designing drugs by simulating the interaction between receptors and drugs and plays an important role in revealing the mechanism of action between active components and body targets (Yuan et al., 2021). It is a common strategy to explore the potential mechanism of action of drugs on diseases by combining network analysis and molecular docking.

The introduction of molecular networking provided an opportunity to discover novel compounds in this study. The novel diarylheptanoids were deduced from a cluster of the network map structures of molecular networking. At the same time, the chemical components of CR-SR, CR, and SR water extracts were subjected to a comprehensive analysis. The cyclic dipeptide and sesquiterpenoid components were analyzed in detail using UPLC-LTQ-Orbitrap MSn technology. The zebrafish xenograft HepG2 model was used for the first time to study the anti-liver cancer activities of CR-SR, CR, and SR in vivo, and the mechanism of action was explored by combining network pharmacology, molecular docking, and RT-qPCR technology. This study provided a solid foundation on the therapeutic material basis and mechanism of action for the anti-liver cancer activities of CR-SR, CR, and SR. A flow chart of the study process is shown in Figure 1.

FIGURE 1.

FIGURE 1

Flow chart of the study process.

2 Materials and methods

2.1 General experimental procedures

The UPLC-MS was carried out on a Thermo Dionex UltiMate 3000 system (Thermo Fisher Scientific, United States ) using an Agilent XDB-C18 column (4.6 × 150 mm, 3.6 μm) and a Thermo LTQ-Orbitrap Velos Pro Hybrid (Thermo Fisher Scientific, United States ) equipped with an ESI source operating in the auto-MSn mode. Trichloromethane, isopropyl alcohol, and anhydrous ethanol were provided by Fuchen Chemical Reagent Co., Ltd. (Tianjin, China). NaCl, KCl, CaCl2, NaHCO3, Na2HPO4, KH2PO4, and MgSO4.7H2O (analytical reagent grade) were purchased from Beijing Chemical Plant Co., Ltd. (Beijing, China). RPMI 1640 and fetal bovine serum (FBS) were ordered from Biological Industries. Pancreatin was obtained from Servicebio. Penicillin and streptomycin were purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Beijing, China). Cell-Counting Kit-8 was purchased from LABLEAD. DiO fluorescent dye was purchased from Beyotime Biotechnology (Beyotime, China). The tissue Total RNA Isolation Kit, RNase free, 4 × gDNA wiper Mix, 5 × HiScript III qRT SuperMix, ChamQ SYBR Color qPCR Master Mix, and HiScript III-RT SuperMix for qPCR were purchased from Vazyme Biotech Co., Ltd. (Nanjing, China).

2.2 Plant material

CR and SR were provided by Hebei Anguo Medical Materials Corporation (Anguo, China) and identified as Curcuma kwangsiensis S.G. Lee et C.F. Liang and Sparganium stoloniferum Buch.-Ham., respectively, by Professor Jing-Juan Wang from the Beijing University of Chinese Medicine, China. The voucher specimens (20180327 and 170201001) were stored in laboratory B417 at the Beijing University of Chinese Medicine.

2.3 Extraction

The botanical drug pair (200 g, CR-SR = 1:1) was decocted with deionized water three times for 2 h each. Then, the supernatant was concentrated under reduced pressure, and finally, a dried extract was obtained. The single botanical drugs CR (200 g) and SR (200 g) were treated in the same way.

2.4 Chemical profiling

2.4.1 Molecular networking analysis

All instruments were controlled by the Xcalibur data system. The data acquired from the previous research were carried out by analyst software Xcalibur 2.1 (Thermo Fisher Scientific, Bremen, Germany) (Chang et al., 2020). The mass spectral data were converted from the raw format to the mzXML format using the msConvert. Then, the file was uploaded to the Global Natural Products Social Networking (GNPS) analysis platform (https://gnps.ucsd.edu) to build a molecular network (Xue et al., 2021). In the (GNPS) web-based platform, the basic parameters were modified to m/z 0.02 for the mass tolerance of precursor and fragment ions used in the MS/MS spectral library. Furthermore, the cosine fraction threshold was set to 0.6, and the results were visualized by Cytoscape 3.8.2 software.

2.4.2 UPLC-LTQ-Orbitrap MSn analysis

The separation of analytes was achieved using the gradient elution system consisting of acetonitrile (A) and 0.05% aqueous formic acid (B) at a flow rate of 0.3 ml/min. The gradient program was as follows: 0–5 min, 3%–12% A; 5–11 min, 12%–20% A; 11–14 min, 20%–25% A; 14–17 min, 25%–30% A; 17–19 min, 30% A; 19–20 min, 30%–35% A; 20–22 min, 35% A; 22–25 min, 35%–40% A; 25–28 min, 40%–48% A; 28–30 min, 48%–52% A; 30–35 min, 52%–80% A; and 35–40 min, 80% A. Then, 1 µL aliquot of each sample was injected into the column, which was maintained at 35°C.

Data acquisition of the mode scan was performed from m/z 50 to m/z 1000 at a resolution of 30,000 in both positive and negative modes. The following ESI parameters in the negative ion mode were optimized and used: a capillary temperature of 350°C, sheath gas flow rate of 40 arb, auxiliary gas flow rate of 10 arb, electrospray voltage of −3.5 V, and tube lens voltage of −120 V. The electrospray voltage was 3.4 V, and the tube lens voltage was 120 V in the positive ion mode. Other parameters were the same as those of the negative ion mode. The most intense ions detected in the full-scan spectrum were selected for the data-independent scan. The relative collision energy for collision-induced dissociation was set to 35% of the maximum.

2.5 Network analysis and molecular docking

2.5.1 Target prediction

The compounds collected from the identification of chemical components by molecular networking and UPLC-MSn analysis included 59 diarylheptanoids, 32 sesquiterpenoids, 21 cyclic dipeptides, and 40 phenols and organic acids (Chang et al., 2020; Wang et al., 2020). The active compounds were further screened based on oral bioavailability (OB) ≥ 30 and drug-like properties (DL) ≥ 0.18, and their predicted targets were obtained by TCM Systems Pharmacology (TCMSP) (https://old.tcmsp-e.com/tcmsp.php) and the Swiss target prediction database (http://swisstargetprediction.ch/). The disease targets were collected by searching for the keywords “liver cancer” in the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/), DrugBank (https://go.drugbank.com/), and Online Mendelian Inheritance in Man (OMIM, http://www.omim.org/). All predicted targets were standardized into official gene symbols using the UniProt database (https://www.uniprot.org/).

2.5.2 Network construction

Network construction was performed as follows: 1) the active compound–target network; 2) protein–protein interaction (PPI) network. We constructed a Venn diagram to determine the overlapping targets between the active compound targets and disease targets using Venny online (https://bioinfogp.cnb.csic.es/tools/venny/). These overlapping targets might play an important role when CR-SR, CR, and SR treat liver cancer. The intersection was considered as the potential targets and inputted to the STRING (https://string-db.org/) database to construct the relationship between proteins. The TSV format of the PPI network was downloaded and visualized by Cytoscape 3.8.2 software (Lan et al., 2020).

2.5.3 Pathway enrichment

The key targets were put into the Metascape database, and the species were set as “Homo sapiens,” with p < 0.01 from the results of PPI analysis. GO annotations of targets and KEGG pathways were enriched and analyzed through the Metascape (http://metascape.org) database platform, which could analyze the biological processes and pathways of genes (Yu et al., 2021). In addition, the correspondence was established among active compounds, key targets, and the top 20 pathways of the KEGG pathway enrichment analysis results and visualized by Cytoscape 3.8.2 software.

2.5.4 Molecular docking

The docking was carried out by the CDOCKER module in the Discovery Studio 2016 package. The key targets were imported into the Protein Data Bank (https://www.rcsb.org/) database to download protein in the PDB format. The 3D structures of the active compounds downloaded from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) were dealt with ChemDraw software. The docking results were evaluated with a threshold of 80% docking score for the original ligand and receptor after determining the docking pocket coordinates. Generally, the binding capacity is stronger when the docking score values are higher than the threshold value (Yuan et al., 2021).

2.6 Cell culture and zebrafish husbandry

The HepG2 cell line was purchased from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, China. The cells were maintained in RPMI 1640 with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin at 37°C in an air–5% CO2 incubator at constant humidity (Chen et al., 2018).

The wild-type (AB stain) zebrafish was purchased from the laboratory of Bo Zhang at Peking University. The zebrafish were maintained and raised in a continuous flow system (ESEN, Beijing, China) on a 14-h light/10-h dark cycle at 28.5°C and fed brine shrimp three times daily. The zebrafish embryos were obtained from spawning adults with a sex ratio of 1:1 (5–8 months old) and raised at 28.5°C in embryo water (5.4 mmol/L KCl, 0.137 mol/L NaCl, 1.3 mmol/L CaCl2, 0.25 mmol/L Na2HPO4, 0.44 mmol/L K2HPO4, 1.0 mmol/L MgSO4, and 4.2 mmol/L NaHCO3) (Zhao et al., 2020).

2.7 CCK8 for cell proliferation detection

Cells in the logarithmic growth phase were seeded into a 96-well plate at a density of 4 × 104/ml (100 μL/well) and cultured for 24 h. Cells treated with the medium containing 0.1% DMSO were used as a negative control. CR-SR, CR, and SR extracts were well dissolved in the medium containing 0.1% DMSO, respectively, followed by ultrasonic vibration. The samples (100 μL) of CR-SR, CR, and SR at different concentrations were added to adherent cells with three wells for each group and repeated three times. After 48 h, the fluid was removed, and CCK8 (100 μL) was added to each well and cultured for 2 h. The absorbance was measured at 450 nm in a microplate reader (Beijing Perlong New Technology Co., Ltd., Beijing, China). The data were expressed as percentage inhibition compared with a vehicle (DMSO) control (Chen et al., 2018).

2.8 Anti-liver cancer activity of CR-SR, CR, and SR extracts in a zebrafish HepG2 xenograft model

To determine the maximum non-lethal concentration (MNLC) of these drugs, 3 days postfertilization (3 dpf) zebrafish were treated with the testing drugs in 12-well culture plates (20 larvae/well) for 72 h, and mortality was recorded at the end of treatment. The dead larvae were counted daily. Therefore, HepG2 cell suspension was stained by 10 μM DiO for 30 min at 4°C, re-suspended in a medium, and kept at 4°C before injection. Cells were injected into zebrafish embryos at 2 dpf using a microinjector, with approximately 200 cells/embryo. The larvae with the same amount of fluorescence were randomly divided into different groups and transferred to 12-well culture plates (20 per sample, n = 3) at 3 dpf. The groups in this experiment included the normal group, the HepG2 xenograft model group, the positive control group (100 ng ml−1 cisplatin), and the drug groups at different concentrations. A total of 10 zebrafish larvae were randomly selected at 6 dpf and photographed in each group using an Axio Zoom V16 fluorescence microscope (Zeiss, Germany), and the relative fluorescence area was calculated. Then, the inhibitory effect of each antitumor drug was quantitatively evaluated (Zhao et al., 2020).

2.9 Detection of the zebrafish mRNA expression level by the real-time quantitative polymerase chain reaction

The mRNA expression levels of the key genes were measured using RT-qPCR. The zebrafish HepG2 xenograft model was built. Then, 3 dpf zebrafish embryos were transferred into 12-well plates (20 embryos/well) and incubated with CR-SR (500 μg/ml), CR (300 μg/ml), and SR (1,000 μg/ml) at 72 hpf. The total RNA (1 μg) was converted to first-strand cDNAs using a PrimeScript™ RT reagent Kit for reverse transcription. In 20 μL reactions with each of the forward and reverse primers, cDNA, and SYBR Green Mix, RT-qPCR was performed. Thermal cycling was set at 95°C for 5 s and 60°C for 30 s with 40 cycles. Gene expression for each sample was expressed as a threshold cycle (Ct), normalized to the reference gene β-actin (△Ct). The experiment was conducted in triplicate (Lan et al., 2020). Proto-oncogene tyrosine-protein kinase Src (SRC), epidermal growth factor receptor (EGFR), estrogen receptor-α (ESR1), prostaglandin endoperoxide synthase 2 (PTGS2), and amyloid precursor protein (APP) genes were determined, as described previously. The primer sequences of the genes are shown in Table 1 (Carnevali et al., 2010; Lu et al., 2013; Liu et al., 2014; Pashay Ahi et al., 2016; Gu et al., 2020).

TABLE 1.

Primer sequence used for PCR analysis.

Gene Forward Reverse
EGFR 5′-ACG​CAG​ACG​AGT​ATT​TAG​TGC​CCA-3′ 5′-AGT​TTC​CAA​AGC​TGC​TGT​TCA​GGC-3′
ESR1 5′-ACT​GTG​GCT​CGA​TTT​CGG​AGT-3′ 5′-TCC​ACT​GGA​CTG​GAG​CAG​AAT​G-3′
PTGS2 5′-TGG​ATC​TTT​CCT​GGG​TGA​AGG-3′ 5′-GAA​GCT​CAG​GGG​TAG​TGC​AG-3′
APP 5′-GGA​GTT​TGT​GTG​CTG​CCC​AA-3′ 5′-ACC​GTC​ACC​GTC​TTC​ATC​GT-3′
SRC 5′-ACA​CAG​CCC​AAC​ATC​ATC​AA-3′ 5′-TAT​CCG​CTC​TCT​CCT​GTC​GT-3′
β-actin 5′-TCC​CCT​TGT​TCA​CAA​TAA​CC-3′ 5′-TCT​GTT​GGC​TTT​GGG​ATT​C-3′

2.10 Statistical analysis

All the assays were carried out in triplicate, and results were expressed as mean values ± standard deviation (mean ± SD). All statistical analyses were carried out by SPSS (Version 25.0) and Origin 2021. The one-way analysis of variance (ANOVA) test was used to check for significant differences among the groups. Differences between models were considered significant when the p-value was less than 0.05.

2.11 Ethics statement

Zebrafish experiments were conducted according to the Regulation on the Administration of Laboratory Animals (2013 Revision, document number: order no. 638 of the State Council) for experimental care and usage of animals.

3 Result and discussion

3.1 Chemical profiling

3.1.1 Study on molecular networking of mass spectrometry of CR-SR, CR, and SR decoction

Previously, our laboratory has identified 47 linear diarylheptanoids in CR-SR (Chang et al., 2020). On the basis of this study, we further explored the MS data through the GNPS platform. The MS data were visualized by Cytoscape 3.8.2. The spectral similarities were expressed as the cosine score (cos θ), and the larger the cos θ score, the higher the similarity of the MS/MS fragments (Xue et al., 2021). Also, the structurally similar compounds were inferred by using the differences in secondary mass spectra from related nodes. Each node represented a secondary mass spectral map. A total of 1,120 nodes were incorporated into the MS/MS molecular networking of the CR-SR decoction in the positive mode, resulting in 18 molecular clusters and 809 unconnected nodes (https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=078b8a6443d540a88720ff67cc3b06a2). Meanwhile, a total of 1,079 nodes were incorporated into the MS/MS molecular networking of the CR decoction in the positive mode, resulting in 22 molecular clusters and 801 unconnected nodes (https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=87f347a0948e4b92b78cf433b111803a). Based on the clusters in the molecular networking, a total of 12 diarylheptanoids were tentatively identified from CR-SR and CR for the first time in the positive mode.

In our previous research, diarylheptanoids were the main compounds of CR-SR (Chang et al., 2020). In this molecular map, 25 and 23 diarylheptanoids had been identified in the largest clusters from CR-SR and SR, respectively. Taking m/z 311.163 as an example, the compound dissociated into fragment ions [M + H-C7H8O2]+ at m/z 187, [M + H-C10H12O]+ at m/z 163, [M + H-C7H8O2-C2H2]+ at m/z 161, [M + H-C7H8O2-C2H4]+ at m/z 159, [M + H-C10H12O2]+ at m/z 147, and [M + H-C12H14O]+ at m/z 137 by comparison with the reported literature (Cheng et al., 2018). Its adjacent node at m/z 327.158 gave an MS/MS spectrum showing the same characteristic fragments at m/z 147. Therefore, the compound was plausibly characterized as 7-(4-hydroxy-3-methoxyphenyl)-1-phenyl-4-hepten-3-one, and its proposed fragmentation pathway is shown in Supplementary Figure S1. According to references, the cracking pathways of other diarylheptanoid compounds could be inferred. Also, other novel diarylheptanoid structures are listed in Table 2, Figure 2, and Figure 3.

TABLE 2.

Identification of the novel diarylheptanoids of CR-SR and CR decoction by the molecular network.

No. Name t R/min Empirical formula Theoretical mass (m/z) Experimental mass (m/z) Mass error (ppm) MS2 data (measured) CR-SR CR SR
C1 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-4,6-dien-3-one 17.07 C21H23O5 355.15400 355.15265 −3.802 337, 161, 145, and 137 +
C2 5-Acetoxy-1-(4-hydroxyphenyl)-7-(4-hydroxy-3 -methoxyphenyl)-3-heptanone 19.79 C21H25O6 373.16456 373.16287 −4.524 193 +
C3 7-(4-Hydroxy-3-methoxyphenyl)- 1-phenyl-4-hepten-3-one 19.91 C20H23O3 311.16417 311.16275 −4.567 187, 163, 161, 159, 147, and 137 + +
C4 5-Hydroxy-1,7-diphenyl-4,6-dien-3-heptanone 20.08 C19H19O2 279.13795 279.13687 −3.892 133, 131, and 261 +
C5 Tetrahydrobisdemethoxycurcumin 20.46 C19H21O4 313.14343 313.14212 −4.201 147 and 107 + +
C6 Dihyrodemethoxycurcumin 20.88 C20H21O5 341.13835 341.13681 −4.515 323, 189, 147, 146, and 118 + +
C7 1,7-Diphenyl-4-en-3-heptanone 22.60 C19H21O 265.15869 265.15738 −4.947 247 and 161, 143, and 133 + +
C8 1-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-6-heptene-3,5-dione 23.01 C21H23O7 387.14383 387.14203 −4.648 369, 199, 194, and 166 + +
C9 l-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxy-3,5-dimethoxyphenyl)-4,6-heptadien-3-one 23.01 C22H26O6 386.17239 386.12015 −1.549 367, 233, 219, and 175 +
C10 Dihydrobisdemethoxycurcumin 24.73 C19H19O4 311.12778 311.12637 −4.550 225 and 147 + +
C11 1-(4′-Hydroxyphenyl)-7-(3″-methoxyphenyl)-3′4″-epoxy-3-heptanol 27.11 C21H27O4 343.19038 343.15271 −3.760 187, 137, and 131 + +
C12 5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-7-diphenyl-4,6-dien-3-heptanone 28.51 C20H21O4 325.14343 325.14240 −3.185 307, 179, 137, and 131 +
FIGURE 2.

FIGURE 2

MS/MS molecular networking of the CR-SR decoction in the positive mode. The novel compound is in red, and its name and structure are depicted in the left column. The known compound is in yellow, and the name is depicted in the right column.

FIGURE 3.

FIGURE 3

MS/MS molecular networking of the SR decoction in the positive mode. The novel compound is in red, and its name and structure are depicted in the left column. The known compound is in yellow, and the name is depicted in the right column.

3.1.2 Identification of the major components by UPLC-LTQ-Orbitrap MSn

The UPLC-LTQ-Orbitrap MSn method was used for the comprehensive analysis of sesquiterpenoids and cyclic dipeptide components in CR-SR, CR, and SR. The components were identified by the molecular weight, elemental compositions, retention time (t R), and characteristic MS/MS fragment mass spectra compared with those reported in the literature. A total of 53 components were preliminarily identified from CR-SR, CR, and SR. A total of 32 sesquiterpenoids (M5, M12, M14, M16, M18–21, M23–26, M29–31, M33–34, M37–43, M45–48, and M50–53) were detected and tentatively characterized from CR-SR and CR in both positive and negative modes. Among them, nine compounds were detected in the SR extract. Cyclic dipeptides are the common cyclopeptides found in nature (Guo et al., 2009a). A total of 21 cyclic dipeptides (M1–4, M6–11, M13, M15, M17, M22, M27–28, M32, M35–36, M44, and M49) were detected and tentatively characterized from CR-SR, CR, and SR extracts in the positive mode. Therein, 18, 13, and 10 cyclic dipeptides were detected from CR-SR, CR, and SR, respectively. The total ion chromatograms (TIC) of CR-SR, CR, and SR in positive and negative ion modes are presented in Figure 4 and Figure 5. The detailed information and structures of the identified components are shown in Table 3 and Figure 6.

FIGURE 4.

FIGURE 4

TIC chromatograms in the positive mode; (A) CR-SR extract, (B) CR extract, and (C) SR extract.

FIGURE 5.

FIGURE 5

TIC chromatograms in the negative mode; (A) CR-SR extract, (B) CR extract, and (C) SR extract.

TABLE 3.

Summary of components in CR-SR, CR, and SR extracts.

No. Name t R/min Empirical formula Theoretical mass (m/z) Experimental mass (m/z) Adduct Mass error MS2 data (measured) CR-SR CR SR
(ppm)
M1 Cyclo(Tyr-Pro) 6.94 C14H17N2O3 261.12336 261.12238 M + H −3.787 261, 233, 216, 215, 188, 136, and 70 +
M2 Cyclo(Val- Pro) 8.87 C10H17N2O2 197.12845 197.12758 M + H −4.435 197, 169, 154, 152, 151, 141, 124, 113, 98, 72, and 70 + +
M3 Cyclo(Phe-Tyr) 9.06 C18H19N2O3 311.1390 311.13916 M + H 0.452 311, 283, 266, 265, 255, 220, 136, and 120 +
M4 Cyclo(Ala-Pro) 9.70 C8H13N2O2 169.09715 169.09633 M + H −4.974 169, 154, 141, 124, 113, 113, 98, 96, 85, and 70 + + +
M5 Shogasulfonic acid A 9.75 C15H23O7S2 379.08797 379.08624 M-H −4.566 379, 361, 351,334, 318, 299, 219, and 191 + +
M6 Cyclo(Pro-Leu) 10.52 C11H19N2O2 211.14410 211.14313 M + H −4.615 211, 183, 166, 165, 154, 138, 127, 86, 72, and 70 + +
M7 Cyclo(Tyr-Leu) 10.71 C15H21N2O3 277.15350 277.15466 M + H −4.218 277, 249, 232, 231, 221, 220, 204, 186, 164, 136, 86, and 72 +
M8 Cyclo(Ala-Phe) 10.98 C12H15N2O2 219.11280 219.11206 M + H −4.720 219, 191, 174, 173, 163, 146, 129, 120, and 72 + +
M9 Cyclo(Val-Val) 11.64 C10H19N2O2 199.14410 199.14352 M + H −2.934 199, 171, 156, 154, 153, 143, 126, 108, 100, and 72 + + +
M10 Cyclo(Pro-Pro) 12.89 C10H15N2O2 195.11280 195.11201 M + H −4.071 195, 167, 150, 149, 139, 122,111, and 70 +
M11 Cyclo(Ile-Val) 14.50 C11H21N2O2 213.15975 213.15961 M + H −0.678 213, 195, 185, 168, 167, 157, 156, 140, 100, 86, 72, and 69 + + +
M12 Cyclo(Pro-Phe) 14.56 C14H17N2O2 245.12845 245.12747 M + H −4.016 245, 217, 200, 199, 189, 172, 161, 154, 120, 98, and 70 + +
M13 Zedoarondiol 14.56 C15H25O3 253.17982 253.17880 M + H −4.033 253, 235, 225, 217, 207, 189, 175, and 161 + +
M14 Zedoalactone C 15.60 C15H23O4 267.15799 267.15908 M + H −4.101 249, 231, 223, 205, 187, 173, 159, and 145 + +
M15 Cyclo(Pro-Thr) 16.51 C9H15N2O3 199.10698 199.10771 M + H −3.771 199, 181, 171, 154, 153, 143, 126, 115, 98, 74, and 70 +
M16 Shogasulfonic acid B 16.81 C15H17O6S 325.07403 325.07431 M-H 0.845 325, 310, 297, 283, 268, 253, 245, 240, 225, and 217 + +
M17 Cyclo(Ile-Pro) 16.84 C11H19N2O2 211.14410 211.14316 M + H −4.473 211, 183, 166, 165, 154, 138, 86, 70, and 69 + + +
M18 Shogasulfonic acid C 18.01 C15H19O5S 311.09503 311.09477 M-H 0.833 311, 293, 283, 247, 231, 203, 189, and 175 + +
M19 Dihydrocurcolone 18.58 C15H21O3 249.14852 249.14755 M + H −3.897 249, 231, 221, 207, 203, 189, 175, 161, and 157 + +
M20 Curcumafuranol 19.17 C15H21O2 233.15360 233.15250 M + H −4.746 233, 215, 197, 191, 187, 173, 159, and 145 + +
M21 Zedoalactone B 19.31 C15H21O5 281.13835 281.13828 M + H −0.250 281, 263, 253, 245, 237, 235, 227, 217, 201, 199, and 183 + +
M22 Cyclo(Trp-Trp) 19.42 C22H21N4O2 373.16590 373.16422 M + H −4.509 373, 345, 327, 300, 282, 243, 187, and 159 +
M23 Phacadinane C 20.02 C15H19O4 263.12778 263.12650 M + H −4.886 263, 245, 235, 227, 219, 217, 203, and 199 + +
M24 Curcolonol 20.07 C15H21O4 265.14343 265.14215 M + H −4.849 265, 247, 249, 229, 219, 209, 201, 191, 173, 145, and 113 + +
M25 Shogasulfonic acid D 21.08 C15H21O4S 297.11566 297.11550 M-H 0.517 297, 282, 279, 269, 253, 233, 217, 199, 177, and 149 + +
M26 Shogasulfonic acid E 21.16 C15H23O4S 299.13156 299.13115 M-H 1.349 299, 284, 281, 271, 235, 219, 205, and 179 + +
M27 Cyclo(Ala-Ile) 21.37 C9H17N2O2 185.12845 185.12817 M + H −1.536 185, 157, 140, 139, 129, 128, 86, 72, and 69 +
M28 Cyclo(Gly-Phe) 22.45 C11H13N2O2 205.09715 205.09616 M + H −4.847 205, 177, 160, 159, 149, 132, 120, 114, and 58 + + +
M29 Zedoalactone A 22.77 C15H23O4 267.15908 267.15778 M + H −4.887 267, 249, 239, 231, 223, 221, 207, 203, 189, and 187 + +
M30 Furanodienone 23.51 C15H19O2 231.13795 231.13686 M + H −4.743 231, 216, 213, 203, 189, 187, 185, 173, 161, and 145 + +
M31 Furanogermacrene 24.28 C15H21O2 233.1536 233.15256 M + H −4.448 233, 217, 215, 205, 197, 191, 187, 177, 175, 159, 149, and 145 + +
M32 Cyclo(Ala-Tyr) 24.34 C12H15N2O3 235.10771 235.10710 M + H −2.632 235, 207, 190, 189, 179, 162, 144, 136, and 72 + +
M33 Furanocadina-1 (10),6,8-triene- 4-sulfonic acid 24.85 C15H17O4S 293.08441 293.08420 M-H 0.695 293, 213, 211, 199, 197, 159, 157, and 145 + +
M34 Wenyujin K 26.11 C15H19O4 263.12778 263.12650 M + H −4.886 263, 245, 235, 227, 217, 203, and 199 + +
M35 Cyclo(Ile-Ile) 26.67 C12H23N2O2 227.17540 227.17450 M + H −3.981 227, 199, 181, 171, 170, 154, 136, 86, and 69 + + +
M36 Cyclo(Gly-Pro) 26.83 C7H11N2O2 155.08150 155.08093 M + H −3.702 155, 127, 110, 109, 82, 71, 70, and 64 +
M37 Zedoarolide B 26.84 C15H21O5 281.13835 281.13846 M-H 0.290 281, 263, 245, 237, 223, 219, 201, 209, and 191 + +
M38 Curzerenone 28.31 C15H19O2 231.13795 231.13693 M + H −4.410 231, 213, 203, 195, 189, 185, 175, 173, 171, and 161 + +
M39 Germacrone 28.74 C15H23O 219.17434 219.17340 M + H −4.297 219, 201, 191, 177, 163, 159, 149, 145, 137, 131, 123, and 109 + +
M40 Zederone 30.46 C15H19O3 247.13287 247.13171 M + H −4.698 247, 229, 219, 211, 205, 201, 187, and 183 + + +
M41 Zedoalactone D 30.66 C15H21O5 281.13835 281.13745 M + H −3.020 281, 263, 253, 245, 217, 203, 189, 171, 163, and 149 + +
M42 Curdione 30.79 C15H25O2 237.18490 237.18375 M + H −4.876 237, 219, 201, 191, 177, 159, 149, 135, 133, 121, and 107 + +
M43 Curcumol 31.21 C15H25O2 237.18490 237.1875 M + H −4.876 237, 223, 219, 208, 194, 190, 176, and 162 + +
M44 Cyclo(Phe-Ser) 31.54 C12H15N2O3 235.10884 235.10770 M + H 4.769 235, 217, 207, 190, 189, 179, 162, 147, 120, 113, and 60 + +
M45 Furanocadina-1 (10),6,8-triene-4-ol 32.80 C15H19O2 231.13696 231.13795 M + H −4.311 231, 217, 213, 203, 189, 185, 177, 171, 163, 159, 149, and 145 + +
M46 Curcumenol 33.30 C15H23O2 235.16925 235.16829 M + H −4.110 235, 217, 207, 199, 189, 179, 177, 175, 161, 149, and 147 + + +
M47 Curzerene 33.56 C15H21O 217.15869 217.15776 M + H −4.291 217, 199, 189, 175, 171,161, 159, 149, 145, and 123 + + +
M48 β-Elememe 33.99 C15H25 205.19415 205.19507 M + H −4.515 205, 190, 177, 165, 163, 149, 135, 123, and 121 + +
M49 Cyclo(Leu-Ile) 34.56 C12H23N2O2 227.17540 227.17491 M + H −2.771 227, 199, 181, 171, 154, 136, 114,86, 72, and 69 + +
M50 Gweicurculactone 35.46 C15H17O2 229.12230 229.12132 M + H −4.350 229, 214, 211, 201, 185, 173, 159, and 143 + + +
M51 Furanodiene 35.59 C15H21O 217.15869 217.15758 M + H −1.112 217, 199, 189, 175, 161, 157, 147, and 133 + + -
M52 Dehydrocurdione 37.38 C15H23O2 235.16925 235.16824 M + H −4.322 235, 217, 207, 199, 189, 175, 161, and 147 + + +
M53 Aerugidiol 37.79 C15H21O3 249.14852 249.14891 M-H 1.5610 249, 231, 221, 216, 209, 193, 181, and 165 + + +
FIGURE 6.

FIGURE 6

The structures of sesquiterpenoids and cyclic dipeptides identified in CR-SR, CR, and SR extracts.

The sesquiterpenoids were more easily detected in the positive mode. The six sulfonated sesquiterpenoids were only shown in the negative mode. The 32 identified sesquiterpenoids were divided into six categories. The main kind of sesquiterpenoid was the gaiane-type, including compounds M5, M12, M14, M20, M21, M25, M26, M29, M37, M41, M43, M46, M50, and M53. Compounds M16, M30, M31, M34, M39, M40, M42, and M51 were germacrane-type sesquiterpenoids. Compounds M38, M47, and M48 were elemane-type sesquiterpenoids, and compounds M18, M19, and M24 were eudesmane-type sesquiterpenoids. In addition, the cadiane-type sesquiterpenoid M23 and marathon-type sesquiterpenoids M33 and M35 were identified.

Cyclic dipeptides have the same skeleton, which differs only in the side-chain substituent at C (3) and C (6) of the cyclic dipeptide ring. The product ions [M + H-CO]+, [M + H-HCONH2]+, [M + H-CO-HCONH2]+, and [M + H-CO-CO]+ were associated with the cyclic dipeptide skeleton (Furtado et al., 2007). The cleavage pathway of the cyclic dipeptide skeleton is shown in Supplementary Figure S2. A series of low-mass ions associated with amino acid residues and fragmentation patterns [M + H-R]+ were formed by the i-cleavage of amino acid residues. The ions [M + H-CO-CO-R]+ could be considered as diagnostic for substituents at C (3) and C (6). The ions at m/z 60 (C2H6NO, Ser), m/z 70 (C4H8N, Pro), m/z 72 (C4H10N, Val), m/z 74 (C3H8NO, Thr), m/z 120 (C8H10N, Phe), m/z 129 (C5H9N2O2, Ala), m/z 136 (C8H10NO, Tyr), and m/z 159 (C10H11N2, Trp) were characterized as the specific amino acid residues. The ions at m/z 86 (C8H10N) and 69 (C5H9) were indicative of the amino acid residue Ile, while the ions at m/z 86 (C8H10N) and m/z 72 (C3H6NO) indicated the presence of the amino acid residue Leu (Xing et al., 2008; Guo et al., 2009b). Furthermore, the fragment ions at m/z [M + H-C2H4]+ and [M + H-C2H4-2CO-R]+ were produced by Pro. Cyclic dipeptides contained a Ser- or Thr-generated fragment ion at m/z [M + H-H2O]+. The formation of each amino acid residue is shown in Supplementary Figure S2.

3.2 Network analysis and molecular docking

3.2.1 Target prediction

The identified components were used as a chemical information database for network analysis research. After searching for targets, 714, 632, and 428 compound targets in CR-SR, CR, and SR were selected for network analysis, respectively. “Liver cancer” was the keyword used searching for disease-related targets, and 14,026 liver cancer-associated targets were retrieved. Then, 683, 604, and 410 overlapping targets were selected as the potential targets for CR-SR, CR, and SR against liver cancer by the Venn tool (Figure 7A).

FIGURE 7.

FIGURE 7

Network pharmacology of CR-SR in liver cancer treatment. (A) Venn diagram of active compound targets of CR-SR, CR, SR with liver cancer targets. (B) Active compound-target network of the overlapping targets between CR-SR and liver cancer (targets as orange diamond nodes; diarylheptanoids as blue circle nodes; phenols and organic acids as green circle nodes; sesquiterpenoids as purple circle nodes; cyclic dipeptides as yellow circle nodes. (C) The PPI network of the screening targets. (D) Go enrichment analysis (top 10). (E) Bubble diagram of enrichment analysis of KEGG pathway (top 20).

Then, 684, 604, and 410 overlapping targets were selected as the potential targets for CR-SR, CR, and SR against HCC by the Venn tool.

3.2.2 Network construction and analysis

The active compounds and potential targets were imported into Cytoscape 3.8.2 software to visualize the active compound–target network (Chen et al., 2019). In Figure 7B, there were a total of 39 active compounds in CR-SR associated with these potential targets, which consisted of 746 target nodes in the network. Apparently, the same targets could correspond to multiple active compounds, and different targets might also correspond to the same active compounds. The complex characteristics of multi-compound and multi-target effects in the network could be easily detected.

The potential targets were input into the STRING database to construct the PPI network. In this network, there were three main parameters, namely, “degree,” “betweenness,” and “closeness,” which were used as filters to select the key targets. The plug-in CytoNCA was used to extract nodes with higher scores in the network, taking the median of betweenness, closeness, and degrees of freedom as the cut point. The targets above the cut point were considered critical targets (Bao et al., 2020). As shown in Figure 7C, the screened PPI network consisted of 162 nodes and 1,652 edges in CR-SR. These key targets contained SRC, TP53, MAPK1, PIK3CA, EGFR, and ESR1, among others. It is speculated that these targets have an important role in the treatment of liver cancer by CR-SR, which is worthy of further exploration.

3.2.3 Gene function and pathway enrichment

GO annotation analysis and KEGG pathway analysis were conducted on the key targets by using the Metascape platform (Yu et al., 2021). The results are shown in Figure 7. The top 10 terms in the biological process (BP), cellular component (CC), and molecular function (MF) are displayed in Figure 7D. BP-related items mainly involved protein phosphorylation, positive regulation of protein phosphorylation, and cellular response to nitrogen compounds. As for CC-related items, potential targets were mainly concentrated in the membrane raft, membrane microdomain, and receptor complex. MF-related items involved kinase activity, protein kinase activity, and phosphotransferase activity. The top 20 pathways of the KEGG enrichment analysis are shown in Figure 7E. KEGG enrichment analysis showed that the main pathways significantly affected were cancer pathways, the PI3K-Akt signaling pathway, and human papillomavirus infection. To further reveal the molecular mechanism of CR-SR anti-liver cancer compatibility, an “active compound–key target pathway” network was constructed. As shown in Figure 8, the networks were visualized by Cytoscape based on the signaling pathways and targets involved.

FIGURE 8.

FIGURE 8

Active compound-key target-pathway network of CR-SR for liver cancer, where green nodes resented active compounds, blue nodes denoted key targets, and orange nodes indicated enriched pathway.

3.2.4 Molecular docking

Molecular docking was used to investigate the possibility of interactions between active compounds and key targets (Chen et al., 2019). Then, according to the results of network analysis and the literature, SRC, EGFR, ESR1, PTGS2, and APP were taken as examples (Liu et al., 2020; Yan et al., 2011; Markosyan et al., 2019; Ren et al., 2016; Di Stadio et al., 2017). Five key targets were used for molecular docking (the key docking parameters are displayed in Supplementary Table S1). Generally, the higher the score, the more stable the conformation is. Since the PDB structure of the target APP does not have a proligand, no in-depth analysis is performed. Prior to docking, the DNA chain and water molecules were removed, and the docking receptor was defined by the original ligand. Also, all ligand compounds were carried out through energy minimization (Liu et al., 2021). Most active compounds had stronger interactions with the key targets than those with the original ligand.

The results of molecular docking showed that diarylheptanoids and cyclic dipeptides had good binding abilities to corresponding proteins. Interestingly, SRC, EGFR, and ESR1 all showed strong affinity abilities with 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane, and PTGS2 showed a good activity for docking with 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-4,6-dien-3-one. In addition, cyclo(Phe-Tyr) and cyclo(Trp-Trp) in cyclic dipeptide and eicosapentaenoic acid in organic acid showed strong affinity abilities with the aforementioned target. The binding modes of some active compounds docked with EGFR, ESR1, PTGS2, and SRC are shown in Figure 9. Taking 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane and SRC as examples, the complex compounds were stabilized by the amino acid residues SER, ASP, and GLU by hydrogen bonds and also bound to ALA, LYS, and VAL by hydrophobic bonds. These docking results indicated the active compounds of CR-SR, CR, and SR had a high binding affinity for key targets of liver cancer.

FIGURE 9.

FIGURE 9

Molecular docking. (A) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the SRC-binding pocket. (B) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the EGFR-binding pocket. (C) Binding modes of 3,5-diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)-heptane in the ESR1-binding pocket. (D) Binding modes of 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-4,6-dien-3-one in the PTGS2-binding pocket.

3.3 Cell proliferation assay

As shown in Figure 10, CR-SR, CR, and SR significantly inhibited the proliferation of HepG2 cells after 48 h. As the concentration of the sample increased, cell proliferation rates gradually decreased. Compared with the model group, the treatment groups showed significantly lower cell proliferation rates (p < 0.01) (Chen et al., 2018). CR-SR showed significant anti-liver cancer activities than CR and SR (Figure 10D). The IC50 values were 1,535, 1,874, and 5,436 μg/ml, respectively. In addition, the SR had the lowest anti-liver cancer activity.

FIGURE 10.

FIGURE 10

Inhibitory effects on the proliferation rate of HepG2 cells. **p < 0.01 compared with the model group. (A) Chart of CR-SR, (B) chart of CR, (C) chart of SR, and (D) line chart of CR-SR, CR, and SR.

3.4 Anti-liver cancer activities of CR-SR, CR, and SR in the zebrafish HepG2 xenograft model

As shown in Figure 11, the maximum tolerance concentrations (MTCs) of CR-SR, CR, and SR were 1,900, 1,200, and 4,000 μg/ml, respectively (Figure 11A). This indicates that the toxicity was ranked as CR > CR-SR > SR. It indicated that SR had the effect of reducing toxicity. The zebrafish HepG2 xenograft model was used to assess the anti-liver cancer activities of CR-SR and CR. Compared to the model group, the growth of the HepG2 cells was significantly inhibited in the drug treatment group.

FIGURE 11.

FIGURE 11

Activity of anti-liver cancer in the zebrafish HepG2 xenograft model. (A) Dose–toxicity curves in 3–6 dpf zebrafish. (B) Effects of CR-SR, CR, and SR on the tumor area in zebrafish (×40). (C) Inhibition rates of the CR-SR, CR, and SR groups. **p < 0.01 compared with the model group.

At the end of the experiment, the tumor area in the model group was the largest, and the fluorescence was bright and clear. Compared to the model group, the tumor area in each treatment group was reduced, and the fluorescence intensity was weakened (Figure 11B). In addition, the inhibition rates of CR-SR were 40.53% at 1,000 μg/ml and 24.11% at 500 μg/ml. The inhibition rates of CR were 35.66% at 600 μg/ml and 17.44% at 300 μg/ml. The inhibition rates of SR were 22.87% at 2,000 μg/ml and 15.68% at 1,000 μg/ml, respectively. As a positive control, the inhibition rate of cisplatin was 74.72% at 0.1 μg/ml (Figure 11C).

Taken together, the results showed that CR-SR, CR, and SR all had anti-liver cancer effects in vivo, which were consistent with those of the cell-level in vitro results (Xu et al., 2015). The inhibition of tumor growth of CR-SR is remarkably better than CR and SR at the concentrations of LC0 and LC0/2, which indicated the inhibitory effect on tumor growth was better than that of single drug pairs (Zhao et al., 2020).

3.5 Effects of CR-SR, CR, and SR on the liver cancer-related mRNA expression level in zebrafish larvae

To clarify the mechanism of anti-liver cancer activities of CR-SR, CR, and SR, the mRNA expression levels were measured for SRC, EGFR, ESR1, PTGS2, and APP. As shown in Figure 12, compared to the control group, the expression levels of SRC, EGFR, ESR1, PTGS2, and APP were apparently upregulated in the model group (p < 0.01 or 0.05), while CR-SR, CR, and SR treatment markedly reversed these key targets. These results demonstrated that CR-SR, CR, and SR might exert an anti-liver cancer effect by downregulating the expression of SRC, EGFR, ESR1, PTGS2, and APP.

FIGURE 12.

FIGURE 12

Expression of SRC, EGFR, ESR1, PTGS2, and APP in zebrafish larvae was detected by RT-qPCR.

4 Discussion

Based on the previous research, 12 new diarylheptanoids were rapidly identified by the similarity of MS/MS fragments in the molecular network (Chang et al., 2020). A total of 53 compounds were tentatively identified by comparing the retention times and MS data of the detected peaks with those reported in the literature, including 32 sesquiterpenoids and 21 cyclic dipeptides. Specifically, 32 sesquiterpenoids and 18 cyclic dipeptides were deduced in CR-SR, and 32 sesquiterpenoids and 13 cyclic dipeptides were inferred in CR. Nine sesquiterpenoids and 10 cyclodipeptide compounds were derived from SR. The results showed that the main source of sesquiterpenoids was from CR, and the cyclic dipeptides were mainly distributed in both CR and SR, indicating that the types of chemical components in CR and SR were similar. On account of there being no fragmentation rules for sesquiterpenoids, the probable fragmentations of a few sesquiterpenoids were proposed based on the reference literature. In addition, fragmentation pathways of cyclic dipeptides were concluded, which provided a reference for the identification of these compounds.

Our previous research showed CR-SR oil had more remarkable anti-cancer activities than CR or SR (Xu et al., 2015). In this study, the anti-liver cancer activities of CR-SR, CR, and SR were evaluated using the HepG2 cell model in vitro and the zebrafish xenograft model in vivo. The result indicated that CR-SR, CR, and SR possessed anti-liver cancer activities, and the activities were ranked as CR-SR > CR > SR, which suggested that their compatibility could enhance the effect on the anti-liver cancer activity. These results were consistent with those of previous studies, which might also justify the rationality of botanical drug pair compatibility (Xu et al., 2015). According to the comparison and analysis of CR-SR, CR, and SR from the chemical profile and pharmacological activities, we found that CR contributes more to the anti-liver cancer activity and SR played an important role in reducing acute toxicity.

Network analysis showed that the mechanism for the anti-liver cancer activities of CR-SR, CR, and SR was multi-component, multi-target, and multi-pathway. The results indicated that the key targets of the pathway in cancer were related to the therapeutic effect of anti-liver cancer activities, including SRC, EGFR, ESR1, PTGS2, and APP (Yan et al., 2011; Ren et al., 2016; Di Stadio et al., 2017; Markosyan et al., 2019; Hunter et al., 2020; Yuan et al., 2021). Specifically, SRC was the non-receptor tyrosine kinase. Under physiological status, the SRC physiological status maintained the foundation of cells, which involved in cell survival and proliferation, while in liver cancer, it significantly interferes with the basic activities of cells. For instance, researchers found that the expression of t-Src in liver cancer tissue is significantly higher than that of non-tumor tissue and positively correlated with the tumor stage and cellular differentiation (Ren et al., 2016; Hunter et al., 2020). EGFR was a transmembrane receptor and was related to the proliferation, angiogenesis, and apoptosis of tumor cells (Yuan et al., 2021). ESR1 in the liver was associated with stimulation of hepatocyte proliferation and was highly sensitive to liver fibrosis or hepatic fibrosis (Yan et al., 2011). PTGS2 plays a key role in antitumor immune suppression, and its immune suppressive functions lead to tumor immune evasion and poor survival (Markosyan et al., 2019). APP is a cell membrane protein that is closely related to tumor growth and metastasis and functions as a tumor-promoting factor in cancer (Di Stadio et al., 2017).

The targets in the aforementioned cancer pathways (SRC, EGFR, ESR1, PTGS2, and APP) were used for molecular docking analysis with all active compounds. The docking results showed that diarylheptanoids and cyclic dipeptides had a good binding ability to the corresponding proteins, which preliminarily verified the accuracy of the network analysis results. Specifically, our research indicated that curcumin and demethoxycurcumin exert inhibitory effects by regulating the EGFR target, and similar results have been reported in the literature (Chen and Xu, 2005; Hatamipour et al., 2018). For example, demethoxycurcumin effectively downregulated heat shock protein 70 and maintained the EGFR function via activating the AMPK pathway (Hatamipour et al., 2018). Furthermore, our results revealed the anti-liver cancer activities of CR-SR, CR, and SR were associated with the PI3K-Akt signaling pathway and human papillomavirus infection. The PI3K/Akt pathway plays a vital role in many ways in cancer, such as cell growth, survival, and apoptosis survival. Activated Akt could catalyze the phosphorylation of a series of proteins, promote tumor cell growth and proliferation, inhibit apoptosis, enhance invasion and metastasis, and act as a central information substance in the process of tumor cell growth (Chen et al., 2017; Feng et al., 2018).

Network analysis techniques rely on predicting targets from existing databases. The content of each compound in TCM was different, so its content was not considered when using this technology for prediction (Huang et al., 2020). Molecular docking was based on the geometric matching algorithm and lowest energy binding mode search. The downside of molecular docking was that it could only predict the possibility of the drug binding to the target. Both had certain limitations (Fornander et al., 2012). The RT-qPCR technology could analyze and verify the expression patterns of related protein-coding genes and improve the precision and accuracy of results. The expressions of SRC, EGFR, ESR1, PTGS2, and APP were detected by RT-qPCR. The results showed that the expressions of the aforementioned targets were downregulated in CR-SR, CR, and SR, which suggested that CR-SR, CR, and SR can exert an anti-liver cancer effect through the inhibition of SRC, SRC, EGFR, ESR1, PTGS2, and APP. The results indicated that our network analysis-based prediction model of molecular mechanisms was reliable to some extent.

In summary, we systematically analyzed the chemical profiles of CR-SR, CR, and SR. Network analysis, molecular docking, and experimental in vivo analysis were used to study the active compounds of the drug pair and the single botanical drugs and to elucidate the mechanisms of CR-SR, CR, and SR against liver cancer. The current method still has room to improve. Apart from computational methods and experimental verification, we can take the dose dependence factor into the network analysis to improve the feasibility and accuracy in future research. The results provided theoretical support for understanding the active compounds and the pharmacological mechanisms of CR-SR, CR, and SR.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

JW and XW designed the method and performed the experiment; GS and XW formulated the research goals; RY provided constructive advice during the article revision process; YD, XZ, and XR contributed to original manuscript preparation; RS, JM, AY, and QF performed the data analyses; JY, DS, and FL performed the experiment and wrote the manuscript; YZ and QD helped perform the analysis with constructive discussions; XL and YH contributed to data curation; SF and CZ performed a review of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1027687/full#supplementary-material

Abbreviations

CR-SR, Curcumae Rhizoma and Sparganii Rhizoma; CR, Curcumae Rhizoma; SR, Sparganii Rhizoma; RT-qPCR, real-time quantitative polymerase chain reaction; TCM, traditional Chinese medicine; GNPS, Global Natural Products Social Networking; MNLC, maximum non-lethal concentration; dpf, days postfertilization; BP, biological process; CC, cellular component; MF, molecular function; SRC, proto-oncogene tyrosine-protein kinase Src; EGFR, epidermal growth factor receptor; ESR1, estrogen receptor-α; PTGS2, prostaglandin endoperoxide synthase 2; APP, amyloid precursor protein; MTC, maximum tolerance concentration.

References

  1. Bao H., Guo H., Feng Z., Li X. (2020). Deciphering the underlying mechanism of Xianlinggubao capsule against osteoporosis by network pharmacology. BMC Complement. Altern. 20 (1), 208. 10.1186/s12906-020-03007-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carnevali O., Tosti L., Speciale C., Peng C., Zhu Y., Maradonna F. (2010). DEHP impairs zebrafish reproduction by affecting critical factors in oogenesis. Plos one 5 (4), e10201. 10.1371/journal.pone.0010201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang Y. L., Xu G. L., Wang X. P., Yan X., Xu X., Li X., et al. (2020). Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs. J. Ethnopharmacol. 250, 112465. 10.1016/j.jep.2019.112465 [DOI] [PubMed] [Google Scholar]
  4. Chang Y. L., Xu G. L., Wang X. P., Yan X., Xu X., Li X., et al. (2020). Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs. J. Ethnopharmacol. 250, 112465. 10.1016/j.jep.2019.112465 [DOI] [PubMed] [Google Scholar]
  5. Chen A., Xu J. (2005). Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (3), G447–G456. 10.1152/ajpgi.00209.2004 [DOI] [PubMed] [Google Scholar]
  6. Chen C., Li H. L., Yi Y., Fan H. J., Chen C. (2019). Network pharmacology-based study on the active substances and mechanism of nao an capsule in treatment of ischemic stroke. Eur. J. Integr. Med. 31, 100976. 10.1016/j.eujim.2019.100976 [DOI] [Google Scholar]
  7. Chen H., Huang Y., Huang J., Lin L., Wei G. (2017). Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol. Rep. 37 (2), 865–870. 10.3892/or.2016.5299 [DOI] [PubMed] [Google Scholar]
  8. Chen S., Luo M., Ma L., Lin W. (2018). Ethylacetate extract from Tetrastigma hemsleyanum inhibits proliferation and induces apoptosis in HepG2 and SMMC-7721 cells. Cancer Manag. Res. 10, 3793–3799. 10.2147/CMAR.S168333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cheng T., Wang G. L., Huo J. H., Wang W, M. (2018). Distribution of exocarp components of Jugland mandshurica in rats' gastric tissues based on UPLC-Q-TOF/MS. Chin. Med. Mat. 49 (11), 2527–2539. 10.7501/j.issn.0253-2670.2018.11.007 [DOI] [Google Scholar]
  10. Di Stadio C. S., Altieri F., Minopoli G., Miselli G., Rippa E., Arcari P. (2017). Role of human GKN1 on APP processing in gastric cancer. Biochimie 135, 149–153. 10.1016/j.biochi.2017.02.007 [DOI] [PubMed] [Google Scholar]
  11. Feng Y., Zu L. L., Zhang L. (2018). MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-κB/MMP-9/VEGF pathways. Oncol. Rep. 39 (5), 2288–2296. 10.3892/or.2018.6289 [DOI] [PubMed] [Google Scholar]
  12. Fornander L. H., Frykholm K., Reymer A., Renodon-Cornière A., Takahashi M., Nordén B. (2012). Ca2+ improves organization of single-stranded DNA bases in human Rad51 filament, explaining stimulatory effect on gene recombination. Nucleic Acids Res. 40 (11), 4904–4913. 10.1093/nar/gks140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Furtado N. A., Vessecchi R., Tomaz J. C., Galembeck S. E., Bastos J. K., Lopes N. P., et al. (2007). Fragmentation of diketopiperazines from Aspergillus fumigatus by electrospray ionization tandem mass spectrometry (ESI-MS/MS). J. Mass Spectrom. 42 (10), 1279–1286. 10.1002/jms.1166 [DOI] [PubMed] [Google Scholar]
  14. Gu X. Q., Yu L., Wu X., Bai Y., Xu X. R., Zhang J., et al. (2020). Research on the effect and mechanism of Bushen Yizhi Formula treating alzheimer's zebrafish model. J. Nanjing Med. Univ. 36 (1), 56–62. 10.14148/ji.ssn.1672-0482.2020.0056 [DOI] [Google Scholar]
  15. Guo Y., Cao S., Wei D., Zong X., Yuan X., Tang M., et al. (2009a). Fragmentation of deprotonated cyclic dipeptides by electrospray ionization mass spectrometry. J. Mass Spectrom. 44 (8), 1188–1194. 10.1002/jms.1595 [DOI] [PubMed] [Google Scholar]
  16. Guo Y., Cao S. X., Zong X. K., Liao X. C., Zhao Y. F. (2009b). Esi-msn study on the fragmentation of protonated cyclic-dipeptides. J. Spectrosc. (Hindawi). 10.3233/SPE-2009-0388 [DOI] [Google Scholar]
  17. Hatamipour M., Ramezani M., Tabassi S., Johnston T. P., Ramezani M., Sahebkar A. (2018). Demethoxycurcumin: A naturally occurring curcumin analogue with antitumor properties. J. Cell. Physiol. 233 (12), 9247–9260. 10.1002/jcp.27029 [DOI] [PubMed] [Google Scholar]
  18. Huang J., Guo W., Cheung F., Tan H. Y., Wang N., Feng Y. (2020). Integrating network pharmacology and experimental models to investigate the efficacy of coptidis and scutellaria containing huanglian jiedu decoction on hepatocellular carcinoma. Am. J. Chin. Med. 48 (1), 161–182. 10.1142/S0192415X20500093 [DOI] [PubMed] [Google Scholar]
  19. Hunter C. A., Koc H., Koc E. C. (2020). c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer. Cell. Signal. 72, 109651. 10.1016/j.cellsig.2020.109651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lan T., Li Q., Chang M., Yin C., Zhu D., Wu Z., et al. (2020). Lei-gong-gen formula granule attenuates hyperlipidemia in rats via cGMP-PKG signaling pathway. J. Ethnopharmacol. 260, 112989. 10.1016/j.jep.2020.112989 [DOI] [PubMed] [Google Scholar]
  21. Le Daré B., Ferron P. J., Couette A., Ribault C., Morel I., Gicquel T. (2021). In vivo and in vitro α-amanitin metabolism studies using molecular networking. Toxicol. Lett. 346, 1–6. 10.1016/j.toxlet.2021.04.006 [DOI] [PubMed] [Google Scholar]
  22. Li S., Zhang B. (2013). Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chin. J. Nat. Med. 11 (2), 110–120. 10.1016/S1875-5364(13)60037-0 [DOI] [PubMed] [Google Scholar]
  23. Liu C., Li J., Wang W., Zhong X., Xu F., Lu J. (2020). miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression. Cell. cycle 19 (10), 1077–1088. 10.1080/15384101.2020.1739808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Liu C. L., Kwok H. F., Cheng L., Ko C. H., Wong C. W., Ho T. W., et al. (2014). Molecular mechanisms of angiogenesis effect of active sub-fraction from root of Rehmannia glutinosa by zebrafish sprout angiogenesis-guided fractionation. J. Ethnopharmacol. 151 (1), 565–575. 10.1016/j.jep.2013.11.019 [DOI] [PubMed] [Google Scholar]
  25. Liu X. Y., Chang Y. L., Wang X. H., Wang Y., Ren X. Y., Ma J. M., et al. (2021). An integrated approach to uncover anti-tumor active materials of Curcumae Rhizoma-Sparganii Rhizoma based on spectrum-effect relationship, molecular docking, and ADME evaluation. J. Ethnopharmacol. 280, 114439. 10.1016/j.jep.2021.114439 [DOI] [PubMed] [Google Scholar]
  26. Lu J. W., Hsia Y., Tu H. C., Hsiao Y. C., Yang W. Y., Wang H. D., et al. (2011). Liver development and cancer formation in zebrafish. Birth Defects Res. C Embryo Today 93 (2), 157–172. 10.1002/bdrc.20205 [DOI] [PubMed] [Google Scholar]
  27. Lu J. W., Yang W. Y., Tsai S. M., Lin Y. M., Chang P. H., Chen J. R., et al. (2013). Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish. Plos one 8 (10), e76951. 10.1371/journal.pone.0076951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lu X., Li B. (2009). Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis. Chin. J. Integr. Med. 15 (5), 395–400. 10.1007/s11655-009-0395-2 [DOI] [PubMed] [Google Scholar]
  29. Markosyan N., Li J., Sun Y. H., Richman L. P., Lin J. H., Yan F., et al. (2019). Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J. Clin. Invest. 129 (9), 3594–3609. 10.1172/JCI127755 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pashay Ahi E., Walker B. S., Lassiter C. S., Jónsson Z. O. (2016). Investigation of the effects of estrogen on skeletal gene expression during zebrafish larval head development. PeerJ 4, e1878. 10.7717/peerj.1878 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ren H., Fang J., Ding X., Chen Q. (2016). Role and inhibition of Src signaling in the progression of liver cancer. Open Life Sci. 11 (1), 513–518. 10.1515/biol-2016-0067 [DOI] [Google Scholar]
  32. Shuo X. U., Jiang W., Kuang Y., Wenfeng X. U., Jin P. (2018). Research advances on zebrafish models in the application of drug screening for antitumor constituents. Northwest Pharm. J. 33 (3), 422–425. 10.3969/j.issn.1004-2407.2018.03.033 [DOI] [Google Scholar]
  33. Tao W., Xu X., Wang X., Li B., Wang Y., Li Y., et al. (2013). Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol. 145 (1), 1–10. 10.1016/j.jep.2012.09.051 [DOI] [PubMed] [Google Scholar]
  34. Wang S., Hu Y., Tan W., Wu X., Chen R., Cao J., et al. (2012). Compatibility art of traditional Chinese medicine: From the perspective of herb pairs. J. Ethnopharmacol. 143 (2), 412–423. 10.1016/j.jep.2012.07.033 [DOI] [PubMed] [Google Scholar]
  35. Wang X. P., Xu G. L., Yin X., Li X., Xu X., Li X., et al. (2020). Phenols and organic acids constituents in water decoction of Curcumae Rhizoma-Sparganii Rhizoma herbal pair and single herb. Chin. J. ETMF 26 (23), 171–179. 10.13422/j.cnki.syfjx.20202113 [DOI] [Google Scholar]
  36. Xing J., Yang Z., Lv B., Xiang L. (2008). Rapid screening for cyclo-dopa and diketopiperazine alkaloids in crude extracts of Portulaca oleracea L. using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22 (9), 1415–1422. 10.1002/rcm.3526 [DOI] [PubMed] [Google Scholar]
  37. Xu G. L., Geng D., Xie M., Teng K. Y., Tian Y. X., Liu Z. Z., et al. (2015). Chemical composition, antioxidative and anticancer activities of the essential oil: Curcumae Rhizoma-Sparganii Rhizoma, a traditional herb pair. Molecules 20 (9), 15781–15796. 10.3390/molecules200915781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Xue X., Jiao Q., Jin R., Wang X., Li P., Shi S., et al. (2021). The combination of UHPLC-HRMS and molecular networking improving discovery efficiency of chemical components in Chinese Classical Formula. Chin. Med. 16 (1), 50. 10.1186/s13020-021-00459-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yan Z., Tan W., Xu B., Dan Y., Zhao W., Deng C., et al. (2011). A cis-acting regulatory variation of the estrogen receptor α (ESR1) gene is associated with Hepatitis B virus-related liver cirrhosis. Hum. Mutat. 32 (10), 1128–1136. 10.1002/humu.21544 [DOI] [PubMed] [Google Scholar]
  40. Yu C. H., Zhao J. S., Zhao H., Peng T., Shen D. C., Xu Q. X., et al. (2019). Transcriptional profiling of uterine leiomyoma rats treated by a traditional herb pair, Curcumae rhizoma and Sparganii rhizoma . Braz J. Med. Biol. Res. 52 (6), e8132. 10.1590/1414-431X20198132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yu J., Wang L., Ding J., Wu L. (2021). Extraction of oleic acid from animals oil and its anti-inflammatory effect on network pharmacology. Iran. J. Sci. Technol. Trans. Sci. 45 (6), 1905–1913. 10.1007/S40995-021-01168-3 [DOI] [Google Scholar]
  42. Yuan C., Wang M. H., Wang F., Chen P. Y., Ke X. G., Yu B., et al. (2021). Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 270, 119105. 10.1016/j.lfs.2021.119105 [DOI] [PubMed] [Google Scholar]
  43. Zhao L. J., Zhao H. Y., Wei X. L., Guo F. F., Wei J. Y., Wang H. J., et al. (2020). The lipid homeostasis regulation study of arenobufagin in zebrafish HepG2 xenograft model and HepG2 cells using integrated lipidomics-proteomics approach. J. Ethnopharmacol. 260, 112943. 10.1016/j.jep.2020.112943 [DOI] [PubMed] [Google Scholar]
  44. Zhao P., Li Z. Y., Qin S. Y., Xin B. S., Liu Y. Y., Lin B., et al. (2021). Three unusual sesquiterpenes with distinctive ring skeletons from daphne penicillata uncovered by molecular networking strategies. J. Org. Chem. 86 (21), 15298–15306. 10.1021/acs.joc.1c01880 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES